Accession Number:

ADA508266

Title:

Modulators of Response to Tumor Necrosis-Related Apoptosis-Inducing Ligand (TRAIL) Therapy in Ovarian Cancer

Descriptive Note:

Annual rept. 1 Apr 2008-31 Mar 2009

Corporate Author:

COLORADO UNIV HEALTH SCIENCES CENTER AURORA CO

Personal Author(s):

Report Date:

2009-04-01

Pagination or Media Count:

18.0

Abstract:

Ovarian Cancer is the leading cause of death from gynecologic cancers in the developed world. We have previously identified a homeobox gene, Six1, which is overexpressed in ovarian cancers as compared to normal ovarian surface epithelium. Overexpression of Six1 is associated with resistance to Tumor Necrosis Factor-Related Apoptosis Inducing Ligand TRAIL based therapies. We have discovered that this resistance in ovarian cancers is likely related to over-expression of the TRAIL decoy receptor DcR2. On-going studies are evaluating the mechanism and significance of this finding on the way to designing new treatments for ovarian cancer.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE